{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-081409","form_type":"8-K","ticker":"BIOA","cik":"0001709941","company_name":"BioAge Labs, Inc.","filed_at":"2025-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.421276+00:00","generated_at":"2026-05-20T00:01:24.843359+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"BioAge provides NLRP3 & APJ program timeline updates in corporate presentation","bullets":["NLRP3 program: IND submission and Phase 1 SAD/MAD initiation planned for mid-2025; initial SAD data expected by end of 2025.","Full Phase 1 SAD/MAD data for NLRP3 program anticipated in mid-2026.","Obesity proof-of-concept data for NLRP3 program expected in second half of 2026.","APJ agonist program (oral and parenteral) expects IND submission by end of 2026.","Company continues to advance both programs, with no financial guidance or data results provided."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-081409","json":"https://secwatch.observer/filing/0000950170-25-081409.json","markdown":"https://secwatch.observer/filing/0000950170-25-081409.md","text":"https://secwatch.observer/filing/0000950170-25-081409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709941/000095017025081409/0000950170-25-081409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709941/000095017025081409/bioa-20250604.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T00:01:24.843359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}